Abacus has more than doubled off its $4.60 low by turning a niche, capital-intensive life-settlements book — buying life insurance policies and collecting the death benefit — into a fast-growing specialty financial, with FY2025 revenue up 110% to $235M. The next leg of the story is a pivot away from the leveraged balance sheet toward capital-light fee income: a stake in Manning & Napier (~$18B AUM) and LifeARC, an AI lifespan-modeling platform. The catch: GAAP EPS of $0.36 sits a fork away from the Street's ~$1.00 adjusted number, and interest coverage is only ~2x.
Abacus Global Management (ABX) is a specialty financial built on the life-settlements market — it buys life insurance policies from people who no longer want them, holds them on its balance sheet, and collects the death benefit, while also brokering settlements and managing alternative-asset funds. FY2025 revenue grew 110% to $235M and the stock has run from a $4.60 low to ~$9.74, near its 52-week high. The bull case is a pivot from a leveraged policy book to a capital-light longevity-data platform — a ~$53M stake in Manning & Napier (~$18B AUM) and the new LifeARC AI lifespan-modeling tool. The hesitation is earnings quality: GAAP diluted EPS of $0.36 versus a Street adjusted number near $1.00, fair-value marks on the policy book that outsiders can't verify, and interest coverage of only ~2x against ~$342M of debt. At ~10x forward adjusted earnings with a near-zero market beta, it is interesting — but the entry, not the business, is doing the work near $10.
Full thesis
Abacus is a genuinely differentiated specialty financial: life-settlement returns are driven by mortality, not markets, which is why its beta sits near zero and why it can compound through cycles that flatten other financials. Revenue more than doubled in FY2025, the dividend yields ~2%, and management is executing a credible pivot from a capital-intensive policy book toward fee-based, capital-light income via the Manning & Napier alliance and the LifeARC data platform — riding a real secular tailwind in aging demographics and the $120T generational wealth transfer. The two things that keep it from being an obvious table-pound: a wide gap between GAAP earnings (diluted EPS $0.36) and the adjusted numbers the Street models (~$1.00), rooted in non-cash fair-value marks on the policy book that are hard for outsiders to verify; and a leveraged, rate-sensitive funding model with interest coverage around 2x. Probability-weighted fair value lands near $10.75 — roughly 10% above the current price and at the low end of a thin analyst target range, because the accounting opacity and funding sensitivity deserve a cautious weighting. The level where the asymmetry genuinely improves is back toward the $7.85 200-day average, where you would be paid to wait on the pivot rather than paying up for it near the highs.
Abacus Global Management: Betting on When We Die, Pivoting to How We Live
A life-settlements specialist that doubled off its lows by turning death-benefit math into 110% revenue growth — now trying to re-rate itself from a leveraged policy book into a capital-light longevity-data platform. The business is genuinely differentiated. The question is the earnings quality, and the leverage.
The Bottom Line
The simplest version of the Abacus thesis: this is a financial company whose profits depend on actuarial tables, not the stock market. It buys life insurance policies from people who would otherwise let them lapse — often older or ill policyholders who need cash more than a death benefit — pays them more than the insurer's surrender value, keeps paying the premiums, and collects the face value when the insured passes. The return is the spread between what it paid and what it collects, discounted over an expected lifespan. Do that across a large, diversified book and you get a stream of returns uncorrelated to equities, which is exactly why ABX carries a beta near zero and why FY2025 revenue more than doubled while the business barely flinched at rates or markets.
The two variables that actually matter over the next 12-18 months are: (1) whether the asset-light pivot — third-party asset management, the Manning & Napier alliance, and LifeARC — scales into real fee income, which would re-rate the company from a leveraged policy book toward a longevity-data platform; and (2) whether the market gains confidence in the earnings quality, because the distance between $0.36 of GAAP EPS and ~$1.00 of Street-adjusted EPS is built on non-cash fair-value marks on the policy book that outsiders can't independently verify. Everything else — the dividend, the TIME growth-list accolades, the conference circuit — is secondary to those two.
Where We've Been
ABX bottomed near $4.60 in mid-2025 as a small-cap, thinly-followed specialty financial that the market wasn't sure how to value. Then a string of strong prints, the name change to Abacus Global Management, a dividend, and a clear strategic pivot toward fee income pulled it all the way back to ~$9.74 — a 112% move that has it pressing its 52-week high of $10.54 and trading well above its $7.85 200-day average. The path was volatile, but the direction has been one way.
ABX share price · Jun 2025 → Jun 2026 (approximate monthly)
The catalysts that moved it
| Date | Catalyst | Significance |
|---|---|---|
| Feb 2025 | Renamed from Abacus Life to Abacus Global Management | Signaled the shift from a pure life-settlements buyer to a diversified alternative-asset manager |
| Mid-2025 | Shares bottom near $4.60 amid small-cap and specialty-financial weakness | A washed-out base for a company the market hadn't figured out how to model |
| FY2025 | Revenue up 110% to $235M; return to GAAP profitability ($36.5M net income) | The growth print that re-rated the story — and beat the Street's own revenue estimate |
| May 27, 2026 | ~$53M minority stake in Manning & Napier + strategic alliance (~$18B AUM) | The clearest step yet toward capital-light, fee-based income and a wealth-advisory platform |
| Jun 5, 2026 | Named to TIME's inaugural World's Growth Leaders of 2026 | Third-party validation of the growth trajectory — sentiment, not fundamentals |
| Jun 10, 2026 | Launched LifeARC, a proprietary AI lifespan-modeling platform | Positions 20 years of mortality data as an "intelligence layer" — the asset-light optionality the bull case needs |
From a Life-Settlements Shop to a Longevity Asset Manager
Founded in Orlando in 2004, Abacus spent its first two decades as a specialist in a market most investors have never traded: life settlements. It went public via SPAC, rebranded twice, and is now trying to convince the market that the data it accumulated buying policies is worth more than the policies themselves.
A life settlement is, at its core, a secondary market for life insurance. Millions of policyholders eventually stop wanting or being able to afford a policy and let it lapse or surrender it back to the insurer for a small cash value. A life-settlement firm steps in and offers more than that surrender value, takes over the premium payments, and collects the death benefit when the insured passes. For the seller, it's often the best economic outcome available for an unwanted asset. For the buyer, it's a fixed-income-like return whose timing depends on mortality — which is why the asset class behaves so differently from stocks or bonds.
For most of its history, Abacus did this on its own balance sheet: buy policies, hold them, collect. That model works, but it is capital-intensive and leveraged — every policy bought is capital deployed, and growth requires continuously raising debt or equity. The strategic insight behind the 2025 rebrand to Abacus Global Management was that two decades of buying, pricing, and servicing policies had produced something more scalable than the policies: a proprietary mortality and longevity dataset, plus the actuarial machinery to price it. The company reorganized around five divisions — Active Management (the policy book), Originations (brokering settlements), Asset Management (running funds for outside investors), Portfolio Servicing, and Technology Services — explicitly tilting toward the capital-light, fee-bearing ones.
Stop being only a buyer of policies; become a manager of other people's capital. The Active Management book is the legacy engine — real, profitable, but balance-sheet-heavy and rate-sensitive. The pivot is toward Asset Management (managing alternative-investment funds where outside investors put up the capital and Abacus earns fees), Originations (spread income from brokering settlements without holding them), and Technology Services (selling mortality data and tools, now packaged as LifeARC). If that mix shifts far enough, Abacus stops being valued like a leveraged policy book and starts being valued like an asset manager — a much higher-quality, higher-multiple business. The Manning & Napier stake and LifeARC are the two clearest down-payments on that transition.
The result is a company that grew revenue from $44.7M in 2022 to $235M in 2025 — but in a lumpy, accounting-heavy way that reflects the underlying asset class. CEO Jay Jackson has been the public face of the growth-and-pivot narrative, leaning hard into the demographic story: an aging population, a $120T generational wealth transfer, and a life-insurance secondary market that captures only a sliver of the policies that lapse each year. The pitch is that Abacus sits at the intersection of all three.
How the Money Actually Works
Five divisions, but two things to understand: the policy book that drives the headline numbers, and the fair-value accounting that makes those numbers hard to read. The growth is real. The distance between GAAP and adjusted earnings is the entire analytical exercise.
Revenue at Abacus comes from a few distinct sources: realized gains when it sells or matures a policy, unrealized fair-value changes as the policies it still holds appreciate toward their face value, origination fees from brokering settlements, and management fees from its funds. The first two — especially the fair-value marks — are where the complexity lives. As a policy moves closer to maturity (the insured ages), its modeled present value rises, and Abacus books that increase as income even though no cash has changed hands. That is legitimate, GAAP-compliant accounting for the asset class, but it means a big chunk of reported "revenue" and "EBITDA" is non-cash and model-dependent.
The revenue trajectory itself is striking: $44.7M → $66.4M → $111.9M → $235.2M across FY2022–FY2025, with FY2025 alone up 110%. Quarterly, the cadence has been $44M, $56M, $63M, $72M through 2025, with Q1 FY2026 at $59.4M (up ~35% year-over-year). On a trailing basis the business runs at roughly a 71% gross margin and a 45% EBITDA margin — high, but a function of how policy gains flow through the income statement.
For FY2025, Abacus reported GAAP diluted EPS of $0.36 ($36.5M net income). The Street's adjusted estimate for the same year sits near $0.84, and 2026 consensus is around $1.00. That fork exists because the analysts add back items the company also adjusts for, and because GAAP earnings are weighed down by ~$39M of annual interest expense and a ~30% effective tax rate. The honest read is that this cuts both ways: the adjusted number may better reflect the economic value being created on the policy book, but it leans on fair-value marks that an outside investor cannot independently audit. In a year like FY2024, the model produced a GAAP net loss of $24M (diluted EPS -$0.34) even as the Street modeled positive adjusted earnings. Whichever number you anchor on changes the valuation by more than 2x — so the multiple debate is really an earnings-quality debate in disguise.
The balance sheet is the other half of the story. Abacus carries roughly $342M of total debt against ~$423M of equity, with the life-settlement portfolio held as ~$418M of long-term investments. Interest expense ran ~$39M in FY2025 — against which interest coverage is only about 2.1x. And the share count tells you how growth has been funded: weighted shares have climbed from ~50M in 2022 to ~97M in 2025, nearly doubling. The policy book throws off cash (operating cash flow comfortably exceeds net income, an income-quality positive), but scaling it has meant steady recourse to both debt and equity markets. That is the leverage the pivot is partly trying to escape.
Revenue · FY2022–FY2026E
The earnings fork · GAAP diluted EPS vs Street adjusted EPS
FY2025 at a glance
| Metric | FY2025 | Note |
|---|---|---|
| Revenue | $235M | +110% YoY |
| EBITDA | $110M | ~45% margin (model-driven) |
| GAAP net income | $36.5M | Diluted EPS $0.36 |
| Interest expense | ~$39M | Coverage only ~2.1x |
| Total debt | ~$342M | Net debt/EBITDA ~2.7x |
| Diluted shares | ~99M | Up from ~50M in 2022 |
What the bull actually owns
Strip the accounting noise and what you own is a fast-growing specialty financial with a near-zero market beta, a ~2% dividend, and returns driven by mortality rather than rates or equities — a genuine portfolio diversifier in a world where most assets move together.
The optionality is the pivot: Manning & Napier (~$18B AUM) and LifeARC are early attempts to layer capital-light fee income on top of the policy book. If even one of asset management or the data platform scales, the current ~10x forward adjusted multiple looks cheap — which is the bet the Street's Buy consensus is making.
Why the Data Is Harder to Copy Than the Trade
Buying a single life-settlement policy isn't hard. Pricing thousands of them accurately, sourcing them at scale, and funding them cheaply is — and that's where Abacus's twenty-year head start actually lives.
Proprietary mortality data and pricing
The core skill in life settlements is estimating how long an insured will live — get it wrong and the return collapses. Abacus has been pricing, buying, and servicing policies since 2004, accumulating a proprietary dataset on actual mortality outcomes that it now claims to package into LifeARC. A new entrant can buy a policy; it cannot buy twenty years of realized longevity data to calibrate its models against. That data advantage is the closest thing the business has to a durable moat, and it compounds with every policy that matures.
Origination network and scale
Policies have to be sourced — from financial advisors, agents, direct-to-consumer channels, and intermediaries. Abacus has built those relationships over two decades, which both feeds its own book and powers the Originations segment that brokers settlements for others. Scale matters here: a larger, more diversified book smooths out the inherent lumpiness of individual mortality outcomes, and a known buyer gets first look at flow. Sub-scale competitors face both worse pricing data and worse deal access.
Access to capital — a moat that can become a liability
Because the model is capital-intensive, the ability to fund policy purchases cheaply is itself a competitive advantage — and Abacus's public listing, debt facilities, and now its fund-management structures give it more funding options than most private players. But this is a double-edged moat: the same reliance on capital markets that lets it grow becomes a vulnerability if rates rise or credit tightens, which is exactly why the pivot toward managing third-party capital (where investors fund the policies and Abacus earns fees) is strategically important.
The Market, and the Demographic Wave Behind It
Life settlements are a small, fragmented, under-penetrated corner of finance riding a very large demographic tailwind. The opportunity is real; so is the regulatory and reputational sensitivity of trading on when people die.
A large, under-penetrated secondary market
Each year, a substantial face value of US life insurance lapses or is surrendered — policies that policyholders walk away from for a fraction of their economic value. The life-settlement market captures only a small share of that, which is the structural opportunity: as awareness grows and an aging population reaches the point of no longer needing coverage, the addressable flow expands. Layer on the oft-cited $120T generational wealth transfer and you get the demographic thesis Abacus markets — more older policyholders, more unwanted policies, more demand for liquidity from illiquid life-insurance assets.
A fragmented competitive field
The life-settlement industry is fragmented across specialist funds, private buyers, and a handful of larger institutional players, with no single dominant public pure-play of Abacus's profile. That fragmentation is part of the opportunity — Abacus is consolidating data, origination, and capital advantages that smaller players can't match — but it also means there's no obvious "Coca-Cola of life settlements" multiple to anchor to. The asset-management pivot is partly an attempt to step out of this niche valuation box entirely and be compared to alternative-asset managers instead.
Regulation and reputation
Trading on mortality invites scrutiny. Life settlements are regulated state-by-state, with rules around licensing, disclosure, and consumer protection — the sellers are often elderly or ill, which makes conduct and reputation genuinely load-bearing. A regulatory tightening, a high-profile conduct issue, or a shift in how these assets are taxed or treated could raise costs or slow origination. It's not an imminent threat, but it's a permanent feature of the industry that a buyer of the stock is implicitly underwriting.
What would actually expand the story
The bull case rests on Abacus stepping beyond the policy book: asset management (third-party capital funding the policies, Abacus earning fees), Manning & Napier (a wealth-advisory platform with ~$18B AUM and a longevity-data tie-in), and LifeARC (selling the mortality intelligence itself). Any one of these maturing into a material, fee-bearing line is what justifies a re-rating; the risk is they stay strategic talking points rather than becoming real revenue.
Manning & Napier, LifeARC, and the Asset-Light Bet
If Abacus is ever going to escape the low multiple of a leveraged policy book, it happens through fee income and data. Two 2026 moves are the clearest expression of that bet — and the things that have to work for the bull case to pay.
Manning & Napier (closed May 2026). Abacus took a ~$53M minority equity stake and entered a strategic alliance with the diversified wealth and asset manager, joining Callodine Group and East Asset Management as institutional investors. The deal accelerates an Abacus Wealth Advisors platform with ~$18B in AUM and brings Abacus's longevity data and actuarial expertise to Manning & Napier's clients. The strategic point: fee-based AUM is capital-light, recurring, and valued at a far higher multiple than a policy book funded with debt.
LifeARC (launched June 2026). A proprietary AI-powered platform that generates personalized lifespan models from medical history, medications, genetics, and biometrics, drawing on Abacus's ~20 years of mortality data. Management frames it as the "intelligence layer for lifespan-linked finance" — a way to monetize the data asset itself and to anchor products across wealth management, insurance, and annuities to individualized longevity projections.
Asset Management more broadly. Running alternative-investment funds where outside investors supply the capital and Abacus earns management and performance fees — the cleanest version of the capital-light transition.
What makes the pivot credible rather than hand-wavy is that it's built on assets Abacus already owns: the mortality data, the actuarial talent, and the origination flow. LifeARC isn't a from-scratch AI moonshot — it's a productization of twenty years of proprietary data. The Manning & Napier alliance isn't a blind acquisition — it's a minority stake alongside other institutions that plugs Abacus's edge into an existing ~$18B distribution platform. Both are sensible, incremental steps rather than bet-the-company swings.
The reason this section is the crux of the valuation: at ~10x forward adjusted earnings, the market is paying for the policy book and assigning little credit to the pivot. If asset management and the data platform scale into real, recurring fee income, the multiple should expand and today's price looks cheap. If they stall — if LifeARC is a press release more than a product, and the Manning & Napier AUM doesn't translate to Abacus fees — then ABX stays a leveraged, rate-sensitive policy book that deserves the low multiple it has. The bull and bear cases hinge on the same two initiatives.
SWOT
Where Abacus wins structurally, where the thesis leaks, where the upside lives, and what would actually break it.
Strengths
- Near-zero market beta (0.09): Returns driven by mortality, not equities — a genuine portfolio diversifier
- Explosive growth: Revenue +110% in FY2025 to $235M, from a $45M base three years earlier
- Proprietary data moat: ~20 years of realized mortality outcomes a competitor can't quickly replicate
- Cash-generative: Operating cash flow exceeds net income; pays a ~2% dividend
- Credible pivot: Manning & Napier and LifeARC built on assets already owned
Weaknesses
- Earnings opacity: $0.36 GAAP EPS vs ~$1.00 Street-adjusted — built on non-cash fair-value marks outsiders can't audit
- Leverage and rate sensitivity: ~$342M debt, interest coverage only ~2.1x
- Dilution: Share count nearly doubled (50M → 97M) since 2022 to fund growth
- Capital intensity: The legacy model needs continuous capital-markets access to grow
- Thin coverage, small cap: ~$930M, ~6 analysts — limited liquidity and scrutiny
Opportunities
- Asset-light fee income: Third-party fund management re-rates the multiple if it scales
- Manning & Napier: ~$18B AUM platform and a wealth-advisory distribution channel
- LifeARC: Monetizing the mortality dataset as a standalone data/AI product
- Demographic wave: Aging population and $120T wealth transfer expand the lapse-policy flow
- Under-penetrated market: Life settlements capture only a sliver of policies that lapse annually
Threats
- Higher-for-longer rates: Raise funding costs and lower the discounted value of the policy book
- Longevity risk: If insureds live longer than modeled, IRRs compress and marks must come down
- Regulatory/reputational: State-by-state rules and the optics of trading on the deaths of the elderly/ill
- Pivot fails to scale: Fee income stays a talking point and ABX stays a low-multiple policy book
- Multiple compression: Any confidence shock to earnings quality re-rates toward the GAAP number
Bull · Base · Bear
Twelve-month forward scenarios off a ~$9.74 starting price. The variance here is driven by two things: whether the market trusts the adjusted-earnings power, and whether the asset-light pivot earns a re-rating — not by macro, given the near-zero beta.
$14
What has to go right: 2026 adjusted EPS lands near the ~$1.00 Street number and the market believes it. Manning & Napier AUM starts converting to Abacus fees and LifeARC shows real traction. The multiple expands toward ~13-14x forward adjusted EPS as fee mix de-risks the model — roughly the high end of the analyst target range. The "leveraged book becomes a platform" outcome.
$11
The most likely path: Abacus keeps growing the book, the pivot progresses without yet being material, and the multiple holds around ~10-11x forward adjusted EPS. The stock grinds modestly through its 52-week high on earnings rather than a full re-rating — a good business being paid for fairly.
$6.50
What breaks it: Rates stay high or rise, squeezing the ~2x interest coverage and funding costs. A fair-value mark-down or a mortality miss shakes confidence in earnings quality, and the pivot stalls. The multiple compresses back toward GAAP-based skepticism and the stock retraces toward the 200-day and the prior base.
Price scenarios · Jun 2026 → Jun 2027
Time-Horizon Outlook
The near-term is about whether the run off the lows consolidates or extends. The medium-term is about whether the asset-light pivot produces real fee revenue. The long-term is about whether Abacus becomes a longevity-data platform — or stays a well-run policy book that grew into its multiple.
Jun-Sep 2026
The stock is pressing its 52-week high after a 112% run. Expect it to digest the move. The next earnings print is the key test of whether revenue growth and the adjusted-earnings number are holding.
- Whether $10.54 (52-wk high) breaks or caps the move
- Next-quarter revenue growth and any margin commentary
- Risk: a small-cap risk-off wave drags it back toward the 200-day regardless of news
Sep-Dec 2026
The window where the pivot has to start showing up in the numbers — early Manning & Napier fee contribution, LifeARC commercial traction, and growth in the Asset Management segment relative to the balance-sheet book.
- Asset-management/fee revenue growing as a share of the mix
- Evidence LifeARC is a product, not just an announcement
- Risk: rates stay high and funding costs pressure the model
The proof year
If the thesis holds: fee income is a meaningful and growing slice of revenue, the GAAP-to-adjusted gap narrows as the model de-levers, and the market starts valuing Abacus more like an asset manager than a policy book.
- Fee-based revenue becoming material to the mix
- Leverage and interest coverage improving
- Risk: the pivot stalls and growth decelerates as the book matures
The endgame
The long-run bull case: Abacus becomes the data-and-capital hub for lifespan-linked finance — managing third-party longevity capital, licensing LifeARC, and earning fees at scale — at which point a ~$930M cap looks like an early entry. The bear: the niche stays a niche.
- Third-party AUM and data licensing as core revenue
- A genuine asset-manager multiple on a de-levered balance sheet
- Tail risk: regulation or a longevity-assumption reset reshapes the asset class
Risk Matrix
Ranked by what would actually move the stock 15%+ in either direction.
The Bottom Line, Revisited
Strip away the accounting debate and what's left is a genuinely differentiated specialty financial — uncorrelated returns, explosive growth, a credible pivot — that has already run a long way and now trades on numbers you have to take partly on faith.
Abacus is the rare financial whose fortunes don't track the market: it makes money on the spread between what it pays for unwanted life insurance and what it collects at maturity, a return driven by mortality tables rather than the S&P. That's why the beta is near zero, why revenue more than doubled in FY2025 without a tailwind from rates or equities, and why the company is a legitimate diversifier. Layer on a sensible pivot toward capital-light fee income — Manning & Napier's ~$18B AUM and the LifeARC data platform — riding a real demographic wave, and the long-term story is genuinely interesting.
The honest hesitation is about earnings quality and leverage, not the business. The distance between $0.36 of GAAP EPS and ~$1.00 of adjusted EPS rests on fair-value marks an outside investor can't audit, and the legacy model carries ~$342M of debt at only ~2x interest coverage. After a 112% run from $4.60 to nearly its 52-week high, the stock is no longer washed-out — it's pricing in a fair amount of the pivot working. The probability-weighted fair value lands near $10.75, roughly 10% above the current price, with a credible bull case to $14 and an equally credible bear to $6.50.
This is a watchlist name with a real edge, at a price that's fair rather than cheap. The setup that turns it from "interesting but pricey" into "compelling" is a pullback toward the $7.85 200-day — or the prior base near $5 — where you'd be handed a differentiated, growing financial at a multiple that pays you to wait on the asset-light transition instead of paying up for it near the highs.